clinical trial · NCT04917874
A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaDominant Dystrophic Epidermolysis BullosaOpen Label Topical Beremagene Geperpavec (B-VEC)
brief summary
This is a 112-week (approximately two-year) open-label extension study of Beremagene Geperpavec (B-VEC), for participants aged 2 months and older, who have been diagnosed with Dystrophic Epidermolysis Bullosa (DEB). Participants will be dosed weekly with the topical B-VEC therapy. The primary endpoint will be to assess long term safety and tolerability of the topical gene therapy. The study is for those who participated in Phase 3 study, as well as, new participants who were unable to participate in the Phase 3 study, who meet all enrollment criteria.
started
May 25, 2021
primary completion
Jul 31, 2023
completion
Jul 31, 2023
last updated
Apr 9, 2024
official title
Open Label Treatment of Beremagene Geperpavec (B-VEC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol